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ABSTRACT
In anorexia nervosa, serum GH levels are increased under basal
conditions and respond abnormally to provocative stimuli. We report
here, for the first time, an analysis of pulsatile GH secretion in these
patients performed by Cluster algorithm. Seven anorectic and six
normal weight, healthy women underwent serial blood sampling at
20-min intervals from 2030–0830 h for GH estimation. The total area
under the curve (AUC; micrograms per L/min) was elevated 4-fold in
anorectic patients compared to controls (4743.0 6 1520.09 vs.
1148.6 6 519.27; P , 0.01), largely due to an increase in the non-
pulsatile fraction (3212.5 6 990.45 vs. 378.7 6 123.27; P , 0.01).
Accordingly, the valley mean value was higher in anorectic than in
control subjects (5.9 6 2.25 vs. 1.0 6 1.30 mg/L; P , 0.01). Further-
more, pulsatile AUC was also greater in anorectic patients (1530.4 6
654.72 vs. 769.8 6 404.02; P , 0.01) due to a significant increase in
GH peak frequency (5.0 6 0.81 vs. 3.0 6 0.89; P , 0.01). No corre-
lations were observed in these patients between body mass index and
any of the parameters of spontaneous GH release, whereas a positive
correlation was found between insulin-like growth factor I levels and
pulsatile AUC (r2 5 0.583; P , 0.05), peak height (r2 5 0.743; P 5
0.01), peak increment (r2 5 0.801; P , 0.01), and GH valley mean (r2
5 0.576; P , 0.05).
In conclusion, it appears that the enhanced GH secretion in an-
orexia nervosa is the result of an increased frequency of secretory
pulses superimposed on enhanced tonic GH secretion. Although this
latter is consistent with a reduction of hypothalamic SRIH tone, the
former may be accounted for by an increased number of GHRH dis-
charges. Considering that in normal weight and obese subjects pa-
rameters of GH release are negatively correlated with adiposity in-
dexes, the lack of such a negative correlation in our patients suggests
that the enhancement of spontaneous GH release in anorectic pa-
tients is not merely the consequence of malnutrition-dependent im-
pairment of insulin-like growth factor I production, but reflects a more
complex hypothalamic dysregulation of GH release. (J Clin Endocri-
nol Metab 82: 3225–3229, 1997)
THE PATHOPHYSIOLOGY of the GH-insulin-likegrowth factor I (IGF-I) axis in anorexia nervosa is not
fully clarified. In this clinical condition, low IGF-I plasma
levels (1) are associated with high baseline GH concentra-
tions (2) and altered GH responsiveness to several provoc-
ative stimuli. Based on the abnormal GH release after phar-
macological manipulations (3–8), an impairment of central
SRIH tone has been postulated in anorexia nervosa. This
hypothesis, however, is challenged by the normal soma-
totropin responsiveness to arginine infusion (9) and to a
double GHRH iv bolus (6). Hypersomatotropism with low
IGF-I levels is observed in other diseases associated with
malnutrition. Both chronic undernutrition (marasmus and
kwashiorkor) and acute dietary restriction (fasting) induce a
marked reduction of plasma IGF-I levels (10–13). Fasted
humans display increased 24-h integrated GH concentra-
tions due to augmented pulse frequency and amplitude (14).
Low IGF-I levels have also been described in critically ill,
hypercatabolic patients (15, 16) displaying progressive pro-
tein store wasting despite high calorie parenteral nutrition.
In these patients, however, pulsatile GH release appears to
be limited, displaying low values of mean serum concentra-
tion, mean secretion rate, amount per secretory burst, and
secretory burst amplitude (16). Anorexia nervosa is a model
of particular interest, because fasting and protein depletion
coexist (17). For this reason, we elected to analyze, by means
of a pulse detection algorithm, the pattern of spontaneous
nocturnal GH release in this clinical condition, an issue ad-
dressed only using chronobiological approaches to date (18).
Subjects and Methods
Subjects
Seven women suffering from anorexia nervosa (age, 21.2 6 4.85 yr;
mean 6 sd) and six normal weight healthy women of comparable age
(21.6 6 3.26 yr) were investigated. All patients met the diagnostic criteria
for anorexia nervosa, subgroup severe food restriction, according to the
DSM-IV (19). Clinical characteristics of the patients and controls are
shown in Table 1. The mean body mass index (BMI), defined as weight
divided by the square of the height, was 13.4 6 1.13 kg/m2. All anorectic
women exhibited a marked food refusal, with an estimated caloric intake
of 600–800 Cal daily. None of them presented bingeing or vomiting
behavior. Secondary amenorrhea was a constant feature. At the time of
the study, weight was stable, and none of the patients had been taking
medications for at least 12 months. Control subjects (BMI, 21.5 6 1.37
kg/m2) were in good general health, were nonsmokers, and had not
undertaken any transmeridian travel for at least 4 weeks. A medical
evaluation, including history, physical examination, and routine blood
chemistry, revealed no abnormalities. Their weight had been stable
during the previous 3 months. All of them were eumenorrheic and were
evaluated during the early follicular phase (second to fifth day) of the
menstrual cycle.
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Experimental protocol
All subjects were studied as in-patients in our department. Control
subjects were admitted to the metabolic ward the day before the study,
whereas anorectic patients had been hospitalized for at least 3 days.
Healthy controls were instructed to consume a weight-maintaining diet
with 50% carbohydrate for the 3 days preceding the investigation. An-
orectic patients were fed a standardized diet (750 Cal/day) containing
50% carbohydrate for 3 days until the study night. Informed consent to
participate in this study was obtained from normal subjects and from
patients or their parents after full explanation of the experimental nature
of the study, which was approved by the ethical committee of our
institution.
Blood samples for evaluation of plasma IGF-I and serum estradiol (E2)
levels were collected in the morning after an overnight fast in all patients
and controls. An indwelling heparin lock catheter was inserted into an
antecubital vein at 1800 h, and serial blood sampling for GH estimation
was initiated at 2030 h and continued at 20-min intervals for 12 h. All
subjects were instructed not to eat during the night and had a normal
nocturnal sleep pattern. To prevent sleep disruptions during the night,
both patients and controls slept in their hospital rooms, and a curtain
was used to separate investigators from the sleeping subjects when
taking samples. Blood was collected into prechilled glass tubes, and
samples were immediately centrifuged at 2300 3 g for 15 min at 4 C;
serum was removed and stored at 280 C until assayed.
Assays
Serum GH and plasma IGF-I concentrations were measured by spe-
cific RIA [Technogenetics, Recordati (Milan, Italy) and Nichols Institute
Diagnostics (San Juan Capistrano, CA), respectively]. IGF-I levels were
determined without prior serum extraction. Detection limits are 0.2
mg/L for GH (double incubation procedure increasing assay sensitivity)
and 19 ng/mL for IGF-I, respectively. Each assay comprised samples
obtained from controls and anorectic subjects. The mean intraassay
coefficients of variation (CVs) at mean GH concentrations of 0.48, 0.88,
2.0, 4.9, 7.9, 9.7, 13.2, and 31.6 mg/L were 24.7%, 17.7%, 9.9%, 5.0%, 5.7%,
2.9%, 8.3%, and 9.1%, respectively, and the interassay CVs at mean GH
concentrations of 2.0, 4.9, 9.7, 13.2, and 31.6 mg/L were 9.9%, 6.6%, 2.9%,
8.7%, and 9.8%, respectively. Intra- and interassay CVs for IGF-I were
5.1% and 10.1%, respectively. In our laboratory, the normal range for
plasma IGF-I in 20-yr-old female subjects is 86–420 ng/mL.
Serum E2 levels were measured by a competitive chemiluminescent
immunoassay (Ciba Corning Diagnostics Corp., Medfield, MA). The
sensitivity of the assay was 37 pmol/L. Intra- and interassay coefficients
of variation were 9.4% and 9.8%, respectively. The normal range for the
follicular phase of the menstrual cycle is 70–300 pmol/L.
Calculations
The secretory GH profiles were analyzed by the Cluster pulse de-
tection algorithm (20), which defines significant hormonal excursions in
relation to the actual experimental variance; a peak is defined as a
statistically significant increase in a cluster of GH values followed by a
statistically significant decrease in a second cluster of values. The un-
detectable samples (,0.2 mg/L) were assigned an arbitrary fixed value
of 0.1 mg/L, which is half the detection limit of our assay. A 1 3 1 cluster
configuration (one sample in the test nadir and one in the test peak) was
used with a t statistic of 2.32 for both the significant up-strokes and
down-strokes. Using these parameters, the probability of the false pos-
itive error rate is constrained to less than 5%. The minimum threshold
for a peak was set at 0.6 mg/L, i.e. 3 sd above the detection limit of GH
assay. Cluster was used to calculate peak frequency (number of signif-
icant GH peaks per 12 h), interpeak interval (time in minutes separating
consecutive peak maxima), peak duration in minutes, peak height (max-
imal GH concentration in a peak), incremental peak height (the differ-
ence between the largest peak value and the preceding nadir), interpeak
valley value (defined as regions between the significant down-strokes
and up-strokes), area under the curve (AUC), and pulse area (integrated
concentration under a peak in excess of the mean pre- and postpeak
nadirs). The areas of GH release were calculated using the trapezoidal
rule. The proportion of the total AUC contained within GH concentra-
tion pulses (pulsatile AUC) was calculated as the product of the pulse
frequency and the mean pulse area. The difference between the total
AUC and the pulsatile AUC was denoted the basal AUC.
The mean nocturnal GH concentration was calculated as the mean of
GH concentrations recorded over the 12-h sampling period.
Statistical analysis
Statistical evaluation was performed by nonparametric Mann-Whit-
ney rank sum test to compare the significance of differences between
groups and by the Wilcoxon signed rank test to assess changes within
the same group.
Linear regressions of BMI and IGF-I on GH peak parameters were
performed in anorectic patients to determine the relationships between
measures of GH release and these parameters. A computer program was
used for all statistical calculations (StatView IV, Abacus Concepts,
Berkeley, CA). All results are expressed as the mean 6 sd. The level of
statistical significance was set at P , 0.05.
Results
Figure 1 shows nocturnal serum GH levels in two repre-
sentative anorectic and control subjects. In normal women,
GH was released in large bursts separated by periods of
secretory quiescence, with baseline GH concentrations fre-
quently approaching assay sensitivity. Only 17.5% of all sam-
ples obtained from normal women had undetectable GH
concentrations. The mean nocturnal GH concentration was
1.5 6 0.71 mg/L (range, 0.4–2.4 mg/L). In contrast, in ano-
rectic patients, the episodes of GH release were superim-
posed on sustained baseline hormone levels; in fact, in none
of the samples drawn from these patients were GH levels
below the detection limit of the assay. In these patients the
mean nocturnal GH concentration was significantly in-
creased compared to that in the control subjects (6.5 6 2.10
mg/L; range, 4.4–9.6 mg/L; P , 0.01 vs. controls).
The results of the Cluster analysis are summarized in Table
2. The mean 12-h AUC was 4-fold higher in anorectic patients
than in normal women due to an increase in both basal and
pulsatile AUC. The valley mean, an index of basal GH re-
lease, was also elevated in anorectic compared to normal
women. Anorectic patients displayed an increased peak fre-
quency with consequently decreased interpeak interval. Ac-
cordingly, the mean pulsatile AUC was significantly greater
TABLE 1. Clinical characteristics of anorectic patients and
control subjects
Subject
no.
Age
(yr)
Wt
(kg)
Ht
(cm)
Duration
of disease
(months)
Anorectic
1 15 33.1 158 13
2 18 28.5 146 24
3 21 37.2 164 61
4 17 35.2 164 15
5 28 34.4 173 121
6 25 39.3 161 72
7 25 43.1 168 114
Mean 6 SD 21.2 6 4.85 35.6 6 4.62 162 6 8.6 60 6 45.2
Control
1 23 52.5 158
2 26 59.3 164
3 24 67.9 168
4 21 45.4 147
5 18 53.2 163
6 18 63 173
Mean 6 SD 21.6 6 3.26 56.8 6 8.11 162 6 8.9
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in anorectic patients than in control women. In patients, the
mean peak height was increased; however, the incremental
peak height did not differ significantly from that in normal
subjects. The pulse area was comparable in the two groups.
The GH peaks in anorectic patients and in normal subjects
were also of comparable widths. The ratio between pulsatile
and total AUC was decreased in anorectic patients compared
to that in control women.
As expected, fasting baseline plasma IGF-I levels were
below the normal range in anorectic patients and were nor-
mal in control subjects [49.4 6 7.84 ng/mL (range, 36.3–63.1
ng/mL) vs. 183.5 6 8.91 ng/mL (range, 164.1–197.0 ng/mL);
P , 0.05]. Serum E2 concentrations were lower in anorectic
patients than in control subjects (174 6 86.4 vs. 283 6 18.6
pmol/L; P , 0.01, respectively).
In anorectic patients, no correlations were observed be-
tween BMI and any of the parameters of GH release, whereas
a positive correlation was found between IGF-I levels and
pulsatile AUC (r2 5 0.583; P , 0.05), peak height (r2 5 0.743;
P 5 0.01), peak increment (r2 5 0.801; P , 0.01), and GH
valley mean (r2 5 0.576; P , 0.05).
Discussion
In the present study the pulse detection algorithm Cluster
has been applied for the first time to analysis of the spon-
taneous GH release in anorexia nervosa. In anorectic pa-
tients, compared to normal subjects, the nocturnal GH se-
cretion is enhanced and characterized by an increase in peak
frequency and interpeak hormonal concentrations. The en-
hanced hormonal release is largely due to an increase in its
nonpulsatile component. Indeed, a clear-cut increase in the
nonpulsatile GH area was observed in anorectic patients.
Although this component constituted less than 40% of GH
release in normal subjects (a figure probably overestimated
by the RIA), it represented up to 70% of GH secretion in
FIG. 1. Serum GH profiles in two representative anorectic patients (upper panel) and in two control women (lower panel).
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anorectic women. However, although some GH peaks may
have been missed in normal women due to the small, but not
negligible, percentage of undetectable samples, the pulsatile
component of GH release was also significantly enhanced in
the patients due to the higher number of secretory episodes
and despite the comparable amount of GH released per
burst. Of note, spontaneous GH release was enhanced in our
patients despite their lower levels of E2, which is a positive
determinant of somatotropin secretion in normal women
(21).
An increase in the GH peak frequency and valley hor-
monal concentrations has also been described in acromegalic
patients (22) and fasted volunteers (14). Acromegaly is char-
acterized by a marked enhancement of nonpulsatile GH re-
lease (22, 23) associated with a moderate increase in the
pulsatile secretory component (22). On the contrary, fasted
volunteers display a significant enhancement of pulsatile GH
release (14, 24), whereas their basal GH secretion, which was
found to be increased in earlier studies (14), was more re-
cently reported to be unchanged (23, 24).
Among the syndromes of acquired GH resistance, the pat-
tern of spontaneous GH secretion in anorexia nervosa ap-
pears to be different from that described in critically ill pa-
tients (16), who display low values of secretory burst
amplitude and GH amount per secretory burst. This dis-
crepancy may reflect pathophysiological differences, be-
cause anorexia, even when associated with important mal-
nutrition and reduction of total body protein (17), is not
characterized by the markedly increased protein catabolic
rate, causing vital tissue wasting with fat depot preservation,
typically observed in long lasting critical illness.
Abnormalities of spontaneous GH secretion similar to
those observed in our anorectic patients, i.e. increased peak
frequency and interpeak GH concentration with unchanged
individual pulse area, are observed in another condition of
cellular fasting, poorly controlled diabetes mellitus (25).
The alteration in spontaneous GH secretion described in
this paper in addition to the abnormalities of somatotropin
responsiveness to pharmacological challenges reported by us
(8) and others (3–7) point to a hypothalamic dysregulation of
GH release in anorexia nervosa. Although the elevated in-
terpulse GH levels are compatible with a reduction of hy-
pothalamic SRIH tone, the increase in GH pulse frequency
might be accounted for by an increased frequency of GHRH
discharges. The former possibility is indirectly supported by
the impaired GH responses to stimuli thought to act via
inhibition of SRIH secretion (7, 8) and is directly strength-
ened by the observation of low SRIH levels in the cerebro-
spinal fluid of these patients (26). However, the reduction of
SRIH tone does not seem to be absolute, as a release of the
neuropeptide is probably elicited by adequate stimuli. This
is suggested by the lack of GH response to the second of two
consecutive GHRH boluses observed in anorexia nervosa (6),
indicating that the SRIH-mediated negative GH autofeed-
back is preserved in these patients.
Although no changes in GH half-life have been reported
in fasted volunteers (24), the possibility that a decreased
metabolic clearance of the hormone contributes to the high
interpulse GH levels in anorexia nervosa cannot be excluded.
The integrity of the IGF-I negative feedback on GH secre-
tion in anorexia nervosa has not been investigated to date.
However, in fasted humans the infusion of recombinant hu-
man IGF-I suppresses the enhanced pulsatile GH secretion
with a similar time course as refeeding, suggesting that
changes in plasma IGF-I concentrations mediate the effects
of nutrition on GH release (27). The lack of a negative cor-
relation between IGF-I levels and the parameters of sponta-
neous GH secretion observed in our patients merges with the
absence of a correlation between somatomedin concentra-
tions and magnitude of the GH response to GHRH reported
by others (28) in suggesting that factors other than or in
addition to the malnutrition-induced lowering of IGF-I are
responsible for the altered GH secretion in anorexia nervosa.
Along the same line is the absence of a negative correlation
between BMI and spontaneous GH release seen in our pa-
tients. This is in sharp contrast with the negative correlation
between BMI or other ponderal indexes and parameters of
spontaneous GH release consistently found in normal weight
(29) and obese subjects (30). We found a positive correlation
between IGF-I levels and pulsatile AUC, peak height, peak
increment, and interpulse GH concentrations. This finding,
if confirmed by an IGF-I assay performed after IGF-binding
protein extraction, would indicate that in anorexia nervosa
high GH levels can partially overcome the peripheral resis-
tance to the hormone.
In conclusion, this study has shown that spontaneous noc-
turnal GH secretion is enhanced in anorexia nervosa due to
an increase in both nonpulsatile and pulsatile components.
This finding together with the lack of negative correlation
between parameters of GH release and nutritional indexes
(BMI and IGF-I concentrations) point to an impairment of the
hypothalamic control of GH secretion in these patients, who,
however, retain some physiological features of GH release,
such as its episodic pattern.
Further studies aimed at better defining GH secretion in
anorexia nervosa and other conditions of GH insensitivity
are recommended.
TABLE 2. Mean pulse parameters of anorectic patients and
normal subjects
Anorectic patients Normal women P
Peak frequency
(no./12 h)
5.0 6 0.81 3.0 6 0.89 ,0.01
Peak width (min) 108.2 6 16.71 101.6 6 36.84 NS
Peak ht (mg/L) 8.6 6 3.37 5.1 6 2.00 ,0.05
Incremental peak
ht (mg/L)
3.0 6 1.39 4.2 6 1.71 NS
Interpeak interval
(min)
114.1 6 27.78 297.2 6 121.08 ,0.01
Valley mean (mg/L) 5.9 6 2.25 1.0 6 1.30 ,0.01
Pulse area
(mg/Lzmin)
323.9 6 182.74 261.2 6 149.16 NS
Total AUC
(mg/Lzmin)
4743.0 6 1520.09 1148.6 6 519.27 ,0.01
Pulsatile AUC (mg/
Lzmin)
1530.4 6 654.72 769.8 6 404.02 ,0.05
Basal AUC (mg/
Lzmin)
3212.5 6 990.45 378.7 6 123.27 ,0.01
Pulsatile/total AUC 0.31 6 0.06 0.62 6 0.16 ,0.05
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